Nebenwirkungen · Blincyto
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion. · Abschnitt 4.8 · PDF-Seite 17–18
HOS-130855 · Präparat HOS-096973
17 MedDRA system Very common Common Uncommon organ class (≥ 1/10) (≥ 1/100 to < 1/10) (≥ 1/1 000 to < 1/100) Skin and subcutaneous Rash11 tissue disorders Musculoskeletal and Back pain Bone pain connective tissue Pain in extremity disorders General disorders and Pyrexia12 Chest pain14 administration site Chills Pain conditions Oedema13 Investigations Hepatic enzyme Weight increased increaseda, 15 Blood alkaline Decreased phosphatase increased immunoglobulins16 Injury, poisoning and Infusion-related procedural reactions17 complications a Additional information is provided in “Description of selected adverse reactions”. b MedDRA high level group terms (MedDRA version 23.0).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:23:00Z · SHA-256 668031da99230a14f14436294725ac020f67d97c55a5ae00fb7031434493482b · Passage 600a118a523d88d6bcd774c86aa09988597c0e778222f7fe0ca2310c4ef93da5 · Zeichen 5028–6169 im Abschnitt